Key Points
-
Prestige Consumer Healthcare is quietly building a stronger OTC healthcare empire.
-
Its $1.045 billion acquisition of Breathe Right, along with Dimetapp and Anbesol, expands its portfolio of category-leading brands and gives it new growth opportunities in sleep, allergy, and wellness.
-
Investors should watch whether management can successfully integrate acquisitions and reduce its elevated debt over the next few years.
When Alphabet joined the Dow Jones Industrial Average (DJINDICES: ^DJI) it marked a significant milestone. Similarly, Warren Buffett’s Berkshire Hathaway elevating it to a top portfolio holding underscores its strategic value. While Alphabet is a robust business, investors focused on long-term gains often find opportunities in quieter, consistent performers.
Prestige Consumer Healthcare (NYSE: PBH) specializes in over-the-counter healthcare products like Monistat, Dramamine, Clear Eyes, Chloraseptic, and BC Powder. Its acquisition of Breathe Right — a prominent nasal strip brand — represents a major step forward. The $1.045 billion deal adds Breathe Right, Dimetapp, and Anbesol to Prestige’s portfolio, positioning it to grow in sleep, allergy, and wellness markets.
The Breathe Right Play
The acquisition brings approximately $200 million in annual revenue and $95 million in EBITDA. Breathe Right, anchored by its longstanding reputation, is now Prestige’s largest brand. CEO Ron Lombardi highlighted potential cross-category expansion, building on past successes like Dramamine’s evolution from motion sickness to broader nausea relief.
Prestige’s strategy focuses on category-synonymous brands, where the product name becomes synonymous with the category itself. Historically, 64% of its revenue stems from such dominant brands, suggesting a scalable model with the Breathe Right addition.
Image source: Getty Images.
A Quieter GLP-1 Angle
Prestige is leveraging its existing brands like Dramamine and Fleet to address side effects associated with GLP-1 weight-loss medications (e.g., nausea, digestive issues). This repositioning requires minimal investment compared to new product development, offering cost-efficient growth in a relevant healthcare trend.
Going International
Beyond Breathe Right, Prestige acquired LaCorium Health in Australia, deepening its presence in a market with established brands like Hydralyte and Fess. International OTC healthcare offers untapped potential due to fragmented markets and consumer loyalty to trusted brands.
Key Risks
The acquisition increased Prestige’s debt to 4.0x EBITDA, requiring strong cash flow management. Success depends on execution, consumer demand, and brand performance. While risks exist, the company’s acquisition model and category leadership provide a foundation for gradual growth.
